Sustainable models require asking what a result shows, what design produced it, and whether the design was built to measure value or just produce a number.
|Articles|June 28, 2019
Supplements and Featured Publications
- Expert Panel: Access to Evidence-based Therapies Is Necessary to Support Individualized Treatment of HIV
Expert Panel: Access to Evidence-based Therapies Is Necessary to Support Individualized Treatment of HIV
Advertisement
This opinion paper, developed by a multidisciplinary panel of HIV experts in 2019 reflects the group’s consensus on recommendations for various stakeholders who work to improve HIV care, including population health decision-makers (such as formulary committees, pharmacy benefit managers, and clinical advisors), advocacy organizations, and local, state, and federal policy makers.
Advertisement
Related to this article
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.
As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.
Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.
Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
Advertisement
Advertisement
Trending on AJMC
1
IRA, 340B, Medicaid: The Policy Pressures on Community Oncology
2
Drug Price Drives Value of MASH Therapies More Than Efficacy
3
Retatrutide Yields Up to 20.8% Weight Loss in Obesity With T2D
4
Vibegron Outranks Mirabegron, Tolterodine on Several OAB Measures
5